In Depth 4 Jul 2022 The COVID-19 pandemic has driven RNA therapeutics into the mainstream As messenger RNA vaccines save lives around the world, and RNA interference drugs are greenlit for rare diseases, the field of RNA therapeutics is now moving faster than ever before. The COVID-19 pandemic proved a turning point for the biotech companies BioNTech and Moderna, which specialize in developing technology based on messenger RNA (mRNA). The […] July 4, 2022 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2022 U.S. biotech financing drops 46% in Q1 compared to 2021 Venture financing deal value for U.S.-headquartered biotech companies dipped by 46% in Q1 2022 compared to Q1 2021, according to analysis from GlobalData. The data and analytics company said the decrease was due to venture capital firms becoming more selective in their investments due to the current economic and geopolitical uncertainties. Mariam Shwea, business fundamentals […] July 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 Progress for hearing preservation trial after Australian approval granted Approval has been granted by the Australian authorities to allow a French company to progress with a clinical trial testing cochlear implants. Montpellier-based Sensorion will start its proof of concept trial of SENS-401, a drug candidate that aims to protect and preserve inner ear tissue from damage. Sensorion is a biotech company specializing in the […] July 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 Companies come together in fight against Dengue Fever A vaccine to treat dengue fever, the mosquito-borne disease, is the end goal of two companies who have signed an agreement to produce and commercialize a lead candidate in the fight against the disease. Emergex Vaccines Holding Limited, a clinical-stage biotech company, recently announced that it has agreed a collaboration with the Molecular Biology Institute […] July 1, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 License submitted to FDA for drug to help those with large B-cell lymphoma A biologics license application has been submitted to the US Food and Drug Administration (FDA) for an antibody to treat patients with B-cell lymphoma. Genmab A/S is a biotechnology company that says its core purpose is to improve the lives of people with cancer. Recently it announced its intent to submit the application for subcutaneous […] July 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022Beyond Biotech podcast 3: Ariceum Therapeutics, TWB, Unilever On this week’s podcast, we have three conversations: with Manfred Rüdiger, CEO of Ariceum Therapeutics; Jon Hague, Unilever’s R&D VP for homecare; and Olivier Rolland, executive director at TWB. Ambrosia and Dionymer winners at 2022 TWB Start-Up Day TWB, which sets up industrial biotechnology R&D projects and designer of innovative and sustainable solutions, announces the […] July 1, 2022 Share WhatsApp Twitter Linkedin Email
In Depth 1 Jul 2022 Continuous cell culture paves the way for better biomanufacturing The development of continuous cell culture technologies is cutting the costs and resources required for biomanufacturing, benefiting biotech processes ranging from growing cultured meat to manufacturing drugs. The idea of replacing livestock with cell culture to produce meat could reduce animal cruelty, lower greenhouse gas emissions and would require far less land to produce equivalent […] July 1, 2022 - 6 minutesmins - By Sachin Rawat Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 FMC dips into pheromone crop protection with $200M BioPhero acquisition FMC Corporation, an agricultural sciences company, has announced a definitive agreement to acquire BioPhero ApS, a Danish pheromone research and production company. The acquisition adds biologically produced pheromone insect control technology to FMC’s product portfolio and R&D pipeline. BioPhero has pioneered a yeast fermentation process for manufacturing pheromones at lower costs and with fewer production […] July 1, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 Symrise Cosmetic Ingredients partners with evoxx technologies Symrise Cosmetic Ingredients has entered into a strategic partnership with German industrial biotech company evoxx technologies. The companies aim to develop biotechnological processes for ingredients used in beauty applications. The companies said as a result, consumers will be able to purchase beauty products with effective and responsible ingredients. Symrise said consumers today consider the ethical […] July 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2022 LG Chem renews license triggering $2M payment to Avacta South Korean clinical stage biopharmaceutical company, LG Chem Life Sciences, has triggered a license renewal fee to UK-based oncology drug company Avacta Group plc. of $2 million. Avacta develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms. Under the terms of the agreement, LG Chem has the exclusive rights to develop […] June 30, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2022 NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders A neuroscience company targeting mitochondrial dysfunction has teamed up with an organization developing small molecule disease-modifying medicines for the treatment for chronic neurogenerative disorders. Domainex, an integrated medicines research services partner has been chosen by neuroscience company, NRG Therapeutics, and will be providing fully integrated lead optimization services including assay biology and medicinal computational chemistry. […] June 30, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2022 Acticor Biotech gets patent for cardiovascular emergency treatment product French company Acticor Biotech has announced the European Patent Office (EPO) has granted a new patent that provides protection for the use of Acticor’s product, glenzocimab in thrombotic diseases in Europe until 2036. The grant in Europe complements the ones already obtained in November 2020 in the U.S. and in November 2021 in Singapore, both […] June 30, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email